Giant Biogene Shares Extend Rally with Over 7% Surge Following CCTV Factory Feature

Stock News04-21

Giant Biogene (02367) saw its shares rise more than 7% again. At the time of writing, the stock was up 5.8%, trading at HK$31.38 with a turnover of HK$189 million. The momentum follows a deep-dive factory visit feature aired by CCTV Finance and CCTV News on April 14. Host Chen Weihong toured Giant Biogene's facilities, detailing the complete process from gene sequence replication to large-scale production of recombinant collagen. The report also disclosed the latest breakthroughs in recombinant collagen transdermal technology, showcasing China's biotechnology prowess from laboratory research to consumer market applications. Changjiang Securities noted that while the company's revenue and profit may face short-term pressure in the second half of 2025, it has demonstrated strong resilience in cost control. With the recent approvals of two Class III medical devices—"Recombinant Type I α1 Subtype Collagen Lyophilized Fibers" and "Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Compound Solution"—the company continues to exhibit leading innovation capabilities and strategic focus. The subsequent commercialization of these two medical aesthetic products, along with the launch of several new skincare items, is highly anticipated. Investors are advised to keep a close watch on the company's new product and business developments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166909557?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166909557","market":"sh","top_or_hot":-1,"title":"Giant Biogene Shares Extend Rally with Over 7% Surge Following CCTV Factory Feature","media":"Stock News","content":"<p>Giant Biogene (02367) saw its shares rise more than 7% again. At the time of writing, the stock was up 5.8%, trading at HK$31.38 with a turnover of HK$189 million. The momentum follows a deep-dive factory visit feature aired by CCTV Finance and CCTV News on April 14. Host Chen Weihong toured Giant Biogene's facilities, detailing the complete process from gene sequence replication to large-scale production of recombinant collagen. The report also disclosed the latest breakthroughs in recombinant collagen transdermal technology, showcasing China's biotechnology prowess from laboratory research to consumer market applications. Changjiang Securities noted that while the company's revenue and profit may face short-term pressure in the second half of 2025, it has demonstrated strong resilience in cost control. With the recent approvals of two Class III medical devices—\"Recombinant Type I α1 Subtype Collagen Lyophilized Fibers\" and \"Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Compound Solution\"—the company continues to exhibit leading innovation capabilities and strategic focus. The subsequent commercialization of these two medical aesthetic products, along with the launch of several new skincare items, is highly anticipated. Investors are advised to keep a close watch on the company's new product and business developments.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Giant Biogene Shares Extend Rally with Over 7% Surge Following CCTV Factory Feature</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGiant Biogene Shares Extend Rally with Over 7% Surge Following CCTV Factory Feature\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-21 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Giant Biogene (02367) saw its shares rise more than 7% again. At the time of writing, the stock was up 5.8%, trading at HK$31.38 with a turnover of HK$189 million. The momentum follows a deep-dive factory visit feature aired by CCTV Finance and CCTV News on April 14. Host Chen Weihong toured Giant Biogene's facilities, detailing the complete process from gene sequence replication to large-scale production of recombinant collagen. The report also disclosed the latest breakthroughs in recombinant collagen transdermal technology, showcasing China's biotechnology prowess from laboratory research to consumer market applications. Changjiang Securities noted that while the company's revenue and profit may face short-term pressure in the second half of 2025, it has demonstrated strong resilience in cost control. With the recent approvals of two Class III medical devices—\"Recombinant Type I α1 Subtype Collagen Lyophilized Fibers\" and \"Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Compound Solution\"—the company continues to exhibit leading innovation capabilities and strategic focus. The subsequent commercialization of these two medical aesthetic products, along with the launch of several new skincare items, is highly anticipated. Investors are advised to keep a close watch on the company's new product and business developments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1166909557","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166909557","pubTimestamp":1776736941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Giant Biogene (02367) saw its shares rise more than 7% again. At the time of writing, the stock was up 5.8%, trading at HK$31.38 with a turnover of HK$189 million. The momentum follows a deep-dive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","BK1207":"个人用品"},"translate_title":"CCTV工厂专题报道后，巨头Biogene股价延续涨势，飙升超过7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1,"VXUS":1},"content_text":"Giant Biogene (02367) saw its shares rise more than 7% again. At the time of writing, the stock was up 5.8%, trading at HK$31.38 with a turnover of HK$189 million. The momentum follows a deep-dive factory visit feature aired by CCTV Finance and CCTV News on April 14. Host Chen Weihong toured Giant Biogene's facilities, detailing the complete process from gene sequence replication to large-scale production of recombinant collagen. The report also disclosed the latest breakthroughs in recombinant collagen transdermal technology, showcasing China's biotechnology prowess from laboratory research to consumer market applications. Changjiang Securities noted that while the company's revenue and profit may face short-term pressure in the second half of 2025, it has demonstrated strong resilience in cost control. With the recent approvals of two Class III medical devices—\"Recombinant Type I α1 Subtype Collagen Lyophilized Fibers\" and \"Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Compound Solution\"—the company continues to exhibit leading innovation capabilities and strategic focus. The subsequent commercialization of these two medical aesthetic products, along with the launch of several new skincare items, is highly anticipated. Investors are advised to keep a close watch on the company's new product and business developments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166909557","isCrawlerRequest":true}